EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp, Sabrina Kraus, Hermann Einsele und 6 weitere

Nuklearmedizin - NuclearMedicine · 01.04.2024 · 63 (02) · 57-61

DOI: 10.1055/a-2194-9965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2024. Verfasst von Rudolf Werner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyNeoplasmsHumansPrecision MedicineProspective StudiesReceptors, CXCR4

Substanzen

CXCR4 protein, humanReceptors, CXCR4

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Clinical Department of Nuclear Medicine, University Hospital AKH Vienna, Wien, Austria.
  • Institute of Experimental Cancer Research, Ulm University Hospital, Ulm, Germany.
  • Department of Medicine III, School of Medicine, Technical University of Munich, Munchen, Germany.
  • Department of Hematology and Oncology, Freiburg University Hospital, Freiburg, Germany.
  • Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.

Zitieren

APA

Werner, R., Haug, A., Buske, C., Heidegger, S., Illert, A. L., Bassermann, F., Herhaus, P., Buck, A., Duell, J., Topp, M. S., Kraus, S., Einsele, H., Lapa, C., Raderer, M., Lenz, G., Habringer, S., von Tresckow, B., & Keller, U. (2024). CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin - NuclearMedicine, 63(02), 57-61. https://doi.org/10.1055/a-2194-9965

Vancouver

Werner R, Haug A, Buske C, Heidegger S, Illert AL, Bassermann F, et al. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin - NuclearMedicine. 2024;63(02):57-61. doi:10.1055/a-2194-9965

BibTeX
@article{Werner2024,
  author = {Werner, Rudolf and Haug, Alexander and Buske, Christian and Heidegger, Simon and Illert, Anna L and Bassermann, Florian and Herhaus, Peter and Buck, Andreas and Duell, Johannes and Topp, Max S and Kraus, Sabrina and Einsele, Hermann and Lapa, Constantin and Raderer, Markus and Lenz, Georg and Habringer, Stefan and von Tresckow, Bastian and Keller, Ulrich},
  title = {CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2024},
  volume = {63},
  number = {02},
  pages = {57--61},
  doi = {10.1055/a-2194-9965}
}
Kostenlos starten →